IL-5 agents may in fact work for severe EGPA manifestations Although severe pt were excluded from enrollment in MANDARA, post-hoc and OLE data suggest development of severe manifestations is rare in benra treated patients @RheumNow #ACR25 https://t.co/slUpAT9mWo

• https://x.com/Dr_Brian_MD/status/1982922182314561831/photo/1

Abstract 1657: Can LLMs track medication history? GPT-4 outperformed most LLMs in identifying TNFi start/stop events and reasons for switch. 💊 Common reasons for TNFi switching: lack of effectiveness, adverse events, and insurance/cost barriers. @RheumNow #ACR25 https://t.co/5FUR9tBoyu

• https://x.com/AkhilSoodMD/status/1982909416413507694/photo/1

#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

• https://x.com/Yuz6Yusof/status/1982900831436615909/photo/1

New tx for IPF/autoimmune ILD, nerandomilast (PDE4Bi) Subgroup analysis from FIBRONEER-ILD, marginally less FVC worsening (-65mL tx grp vs -107mL plbo grp) & no clear improvements in dyspnea/fatigue/cough But also... 6% absolute reduction in overall, persisted (small n) in https://t.co/Faf26UZuDx

• https://x.com/EBRheum/status/1982870661690237240/photo/1
• https://x.com/EBRheum/status/1982870661690237240/photo/1
• https://x.com/EBRheum/status/1982870661690237240/photo/1

Beyond biologics: RA meets bioelectric medicine. In RESET-RA, TNFi inadequate response or intolerant (n=124), vagus nerve stimulation led to significant & durable improvement 🔹 ACR20 3mo: 42% active vs 18% sham (p=0.0057) 🔹 Benefits through 12mo @RheumNow #ACR25 A#1675

This study evaluated effectiveness of SEC in PsA prevention of a subgroup of pts from SELENA: PsO pts w/o PsA & nail dse (n=292) At 5 yrs: 🎯98.3% didn't develop PsA (yEAIR 0.49) 🎯 Sustained PASI, PGA 0/1 💡Longterm SEC effective for PsA prevention? #ACR25 @RheumNow Abs1463 https://t.co/t7P1Oerbrw

• https://x.com/RHEUMarampa/status/1982859839715033097/photo/1

Sun et al. Telitacicept in SARD-ILD (pSS, ASS, RA). 25 patients. Improvements in CT, PFTs, 6MWT. @RheumNow #ACR25 Abstr#1361 https://t.co/q679LOaOyL

• https://x.com/RichardPAConway/status/1982857071872622948/photo/1

In ICONIC-LEAD, adolescents (12 to <18 years) with moderate-to-severe psoriasis treated with icotrokinra (ICO) achieved Investigator Global Assessment (IGA) 0/1 in 84.1% vs 27.3% (placebo) and PASI 90 in 70.5% vs 13.6% at Week 16. Week 24 responses reached 88.6%. Safety profile https://t.co/L7h8BlnWaO

• https://x.com/synovialjoints/status/1982839707932483871/photo/1

Case series of 5 patients with binutuzumab (CD20) in AAV Short story short; it worked. Of course it worked. Obviously it worked. Everyone knew it would work. Why aren't we doing more TRIALS with new/better B cell inhibitors in AAV? #ACR25 @RheumNow Abstr#1601 https://t.co/H6Zz3Tf3xo

• https://x.com/EBRheum/status/1982839203819090389/photo/1

A combined biomarker assay may predict which AAV patients will not respond to RTX therapy A next step towards precision / personalized rheumatology? @RheumNow #ACR25 Abst 1602 https://t.co/gcrZUNV0b9

• https://x.com/Dr_Brian_MD/status/1982836045298184565/photo/1
• https://x.com/Dr_Brian_MD/status/1982836045298184565/photo/1